Evaluating of the phosphodiesterase inhibitor type 5 effectiveness in treatment of neurogenic erectile dysfunction in patients with DM type 1

Kurbatov D.G.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Galstian G.R.

FGBU "Éndokrinologicheskiĭ nauchnyĭ tsentr", Moskva

SPIN RSCI: 9815-7509
Scopus AuthorID: 7003667594

Shvarts Ya.G.

Endocrynology Research Centre, Moscow, Russia

Rozhivanov R.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

SPIN RSCI: 8052-3310
ORCID: 0000-0002-5386-4289

Dubskiĭ S.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Lepetukhin A.E.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Evaluating of the phosphodiesterase inhibitor type 5 effectiveness in treatment of neurogenic erectile dysfunction in patients with DM type 1

Authors:

Kurbatov D.G., Galstian G.R., Shvarts Ya.G., Rozhivanov R.V., Dubskiĭ S.A., Lepetukhin A.E.

More about the authors

Journal: Problems of Endocrinology. 2015;61(4): 24‑28

DOI: 10.14341/probl201561424-28

Downloaded: 3

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kurbatov DG, Galstian GR, Shvarts YaG, Rozhivanov RV, Dubskiĭ SA, Lepetukhin AE. Evaluating of the phosphodiesterase inhibitor type 5 effectiveness in treatment of neurogenic erectile dysfunction in patients with DM type 1. Problems of Endocrinology. 2015;61(4):24‑28. (In Russ.)
https://doi.org/10.14341/probl201561424-28

Close metadata

Urogenital form of autonomous diabetic polyneuropathy is a specific lesion of the autonomic nervous system in patients with diabetes mellitus (DM) and is the main pathogenetic cause of sexual dysfunction in these patients. The most common form of the sexual dysfunction in patients with DM is an erectile dysfunction, the risk of which is at 3 times higher for patients with DM compared to the population without it. Considering that patients with DM are a special group because of the presence of specific complications, preferences in therapy is given to inhibitors of PDE-5 type inhibitors. Aim — optimization of diagnosis and treatment of neurogenic erectile dysfunction caused by urogenital autonomic diabetic neuropathy in patients with type 1 diabetes. Material and methods. The study included 40 patients with DM type 1 at the age of 25.7±6.1 years. The duration of the DM type 1 18±9.7 years. The average level of glycated hemoglobin at the time of inclusion of patients in the study 7.1±1.3%. All patients in addition to general clinical examination performed neuromyography of peroneal nerve and pudendal nerve (at baseline and after a course of therapy with sildenafil) and the analysis of endothelial function on the EndoPat ™ (baseline and after a course of therapy with sildenafil). Results. At baseline, all 40 men s complained on the quality of erection of varying severity. In 30 (75.0%) of men according to a survey on the unit EndoPat ™ determined endothelial dysfunction (RHI 1.45±0.16). In the range of the gray zone (RHI 1.79±0.13) IRG was detected in 7 (16.6%) men. RHI values, indicating normal functioning of the endothelium, were obtained in 3 (8.4%) cases. After 6 weeks, analisys of endothelial function after the course of treatment with sildenafil was repeated: endothelial dysfunction was found in 6 (16.6%) patients, in the range of the gray zone RHI was registered in 14 (33.4%). Evidence about normalized endothelial function were obtained from 20 (50.0%) patients. The results of neuromyomyographic test of n. peroneus and n. pudendus confirmed the presence of distal diabetic neuropathy and urogenital form of autonomic diabetic neuropathy baseline in all patients. Retest after treatment showed a significant positive trend in our patients. Conclusion. Our study showed the advisability of using inhibitiors PDE-5, in particular sildenafil, not only to improve erectile function in patients with DM type 1, but also to improve endothelial function and condition of the peripheral nerves. We are convinced that the examination of such patients should include both of these methods, because diabetic neuropathy in patients with DM directly linked with endothelial dysfunction.

Keywords:

polyneuropathy

erectile disfunction

urogenital neuropathy

Authors:

Kurbatov D.G.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Galstian G.R.

FGBU "Éndokrinologicheskiĭ nauchnyĭ tsentr", Moskva

SPIN RSCI: 9815-7509
Scopus AuthorID: 7003667594

Shvarts Ya.G.

Endocrynology Research Centre, Moscow, Russia

Rozhivanov R.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

SPIN RSCI: 8052-3310
ORCID: 0000-0002-5386-4289

Dubskiĭ S.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Lepetukhin A.E.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

List of references:

Endocrinology: national guidelines. Ed by Dedov I.I., Melnichenko G.A. – Moskow: GEOTAR-Media; 2009. P. 399-407. (In Russ).
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic Autonomic Neuropathy. Diabetes Care. 2003;26(5):1553-1579. doi: 10.2337/diacare.26.5.1553.
Rozhivanov RV, Akimova AN, Dubsky SA, et al. Specific features of urogenital disorders in patients with diabetes mellitus. Diabetes mellitus. 2009;12(2):40-45. (In Russ). doi: 10.14341/2072-0351-5396.
Berrada S, Kadri N, Mechakra-Tahiri S, Nejjari C. Prevalence of erectile dysfunction and its correlates: a population-based study in Morocco. Int J Impot Res. 2003;15(S1):S3-S7. doi: 10.1038/sj.ijir.3900968.
Rozhivanov RV, Suntsov YI. Erektil’naya disfunktsiya u bol’nykh diabetom v Rossiiskoi Federatsii. Trudnyi patsient. 2005;3(9):31-35. (In Russ).
NisÉN HO, Larsen A, LindstrÖM BL, et al. Cardiovascular Reflexes in the Neurological Evaluation of Impotence. Br J Urol. 1993;71(2):199-203. doi: 10.1111/j.1464-410x.1993.tb15918.x.
Crowe R, Milner P, Lincoln J, Burnstock G. Histochemical and biochemical investigation of adrenergic, cholinergic and peptidergic innervation of the rat ventral prostate 8 weeks after streptozotocin-induced diabetes. J Auton Nerv Syst. 1987;20(2):103-112. doi: 10.1016/0165-1838(87)90107-x.
Hecht MJ, Neundörfer B, Kiesewetter F, Hilz MJ. Neuropathy is a major contributing factor to diabetic erectile dysfunction. Neurol Res. 2001;23(6):651-654. doi: 10.1179/016164101101198965.
Harati Y. Diabetes and the Nervous System. Endocrinol Metab Clin North Am. 1996;25(2):325-359. doi: 10.1016/s0889-8529(05)70327-3.
Kurbatov DG, Rozhivanov RV. Vozmozhnosti terapii erektil’noy disfunktsii neyrogennogo geneza ingibitorami fosfodiesterazy 5-go tipa u bol’nykh sakharnym diabetom. Urologiia. 2009;(5):48-49. (In Russ).
Angelis K, Konstantinos G, Anastasios A, et al. The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. Expert Opin Pharmacother. 2009;10(2):155-160. doi: 10.1517/14656560802678211.
Deyoung L, Chung E, Kovac JR, et al. Daily Use of Sildenafil Improves Endothelial Function in Men With Type 2 Diabetes. J Androl. 2011;33(2):176-180. doi: 10.2164/jandrol.111.013367.
Capogrossi MC, Mammi C, Pastore D, et al. Sildenafil Reduces Insulin-Resistance in Human Endothelial Cells. PLoS One. 2011;6(1):e14542. doi: 10.1371/journal.pone.0014542.
Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B. Phoshphodiesterase-5 Inhibitors: Novel Weapons Against Alzheimer’s Disease? Int J Neurosci. 2010;120(12):746-751. doi: 10.3109/00207454.2010.520381.
Hackett G. PDE5 inhibitors in diabetic peripheral neuropathy. Int J Clin Pract. 2006;60(9):1123-1126. doi: 10.1111/j.1742-1241.2006.01087.x.
Efremov EA, Dorofeev SD, Melnik II, et al. High-precision evaluation of systemic endothelial function in the complex diagnosis of erectile disorders. Experimental & clinical urology. 2013;(3):79-82. (In Russ).

Close metadata